Salute e Benessere

Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and…

Target patient enrollment of 92 evaluable patients achieved in the VIRAGE Phase 2b clinical trial of VCN-01 in patients with metastatic pancreatic ductal adenocarcinomaManufacturing funding awarded by the Spanish Government's National Knowledge Transfer ProgramData and Safety Monitoring Committee Review of Phase 1b/2a SYN-004 in allogeneic hematopoietic cell transplant recipients recommends expansion to Cohort 3Orphan Medicinal Product Designation granted by the European...
Nasdaq GlobeNewswire
12/11/2024

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine…

New preclinical data demonstrates that CMV antigens identified with Evaxion's AI-Immunology™ platform trigger targeted immune responses Results also showcase the successful design of a proprietary prefusion glycoprotein B (gB) antigen with ability to neutralize the virusEvaxion is advancing these new findings to develop a multi-component CMV vaccine candidateAbout 1 in 200 babies is born with congenital CMV infection and the virus infects approximately 60% to 70% of adults in...
Nasdaq GlobeNewswire
12/11/2024

OrganOx and eGenesis Announce Exclusive Clinical Co-Development Agreement for…

Partnership aims to advance a novel liver support system integrating a leading organ preservation platform with whole biologic livers to address a major unmet need The companies will focus on the estimated 35,000 patients in the United States hospitalized each year for acute or acute-on-chronic liver failure1,2 . The efficacy of existing liver support options is limited, and patients in liver failure face mortality rates as high as 50 percent 2. For some patients, utilizing a human...
Nasdaq GlobeNewswire
12/11/2024

Ramsay Generale de Sante: preparatory documents availability for the 2024…

PRESS RELEASE Paris, 12 thNovember 2024COMBINED GENERAL MEETING OF DECEMBER 12, 2024 Arrangements for making available or consulting the preparatory documents for the Ramsay Générale de Santé General Meeting of December 12, 2024 The shareholders of Ramsay Générale de Santé are invited to participate in the Combined General Meeting on Thursday, December 12, 2024, which will take place at 10 a.m. at the Apostrophe 83 avenue Marceau 75116 Paris.The meeting notice...
Nasdaq GlobeNewswire
12/11/2024

SciBase announces collaboration for prediction of atopic dermatitis in infants

Inge Kortekaas Krohn, assistant professor SKIN Research Group comments: Inge Kortekaas Krohn, assistant professor SKIN Research Group comments: ''Early detection of a child that is at risk of developing atopic dermatitis and subsequent adequate preventive measures can reduce disease burden and further progression to other atopic diseases like food allergy, allergic asthma or allergic rhinitis. Therefore, the present collaboration holds the potential to improve prediction, prevention and...
PR Newswire
12/11/2024

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024…

Announced additional interim data from ongoing Phase 1 clinical study of ORX750, a novel orexin receptor 2 (OX2R) agonist, in acutely sleep-deprived healthy volunteers that further support best-in-class potential of ORX750 in narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH); Presentation of Phase 1 data planned for medical congress in Q2 2025Initiated Phase 2a clinical study of ORX750 in patients with NT1, NT2 and IH; Phase 2a data across all three...
Nasdaq GlobeNewswire
12/11/2024

Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark…

HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief.* HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief.* "We are thrilled to…
PR Newswire
12/11/2024

iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates

- EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU - Interim data from inupadenant Phase 2 A2A-005 in 2L NSCLC at ESMO-IO - Completed enrollment of EOS-984 Phase 1 monotherapy dose escalation and initiated dosing of EOS-984 + pembrolizumab combination - Pro forma cash and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 across a number...
Nasdaq GlobeNewswire
12/11/2024

Novo Holdings co-leads $181.4 million Series D financing in Alentis Therapeutics…

The oversubscribed Series D round was led by OrbiMed, with Novo Holdings and Jeito Capital acting as co-leads. The financing round included new participation from Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital, and Avego Bioscience Capital, along with continued support from existing backers including notably RA Capital Management, Morningside Venture Investments, BB Pureos and BPI France through its InnoBio 2 fund. The oversubscribed Series D…
PR Newswire
12/11/2024

Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational…

Cash position of $19.6 million as of September 30, 2024 Cash position of $19.6 million as ofSeptember 30, 2024 Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGOandCALGARY, AB , Nov. 12, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced third quarter financial results and operational highlights. Wayne Pisano, Chair...
PR Newswire
12/11/2024

Coloplast A/S - Notice of Annual General Meeting 2024

The Annual General Meeting of Coloplast A/S will be held onThursday, 5 December 2024 at 3:30 pm CETat the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk, Denmark. The notice of the Annual General Meeting is enclosed. For further information, please contactInvestors and analystsAnders Lonning-SkovgaardExecutive Vice President, CFOTel. +45 4911 1111Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45...
Nasdaq GlobeNewswire
12/11/2024

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1…

The Phase 1 clinical trial (CTR20240663) was a randomized, open-label, first-in-human study involving 92 participants, designed to assess the bioavailability, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of GZR18 tablets in healthy adult participants. The study also evaluated the effect of meal timing on the drug's PK, PD, safety, and tolerability. The Phase 1 clinical trial (CTR20240663) was a randomized, open-label, first-in-human study involving 92 participants,...
PR Newswire
12/11/2024

Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to…

·More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults.1 ·DRD is a growing epidemic that is expected to increase as the incidence of diabetes escalates across the globe. 2,3 ·There is an urgent need for earlier detection of DRD and novel treatments that work in earlier disease states before vision loss occurs. Ingelheim, Germany and Ann Arbor, MI, USA,...
Nasdaq GlobeNewswire
12/11/2024

2024 Tsingke High-Impact Literature Compilation - Gene Synthesis

Compilation of High-Impact Literature Compilation of High-Impact Literature 1.Title: Enhancing rice panicle branching and grain yield through tissue-specific brassinosteroid inhibitionDOI:10.1126/science.adk8838 Journal:Science Impact Factor:56.9Summary:This study shows that crop yield potential is limited by inherent trade-offs between grain size and number. While brassinosteroids (BRs) promote grain enlargement, their role in regulating grain number has been...
PR Newswire
12/11/2024

deCODE genetics/Amgen: New Study Explores the Role of BMI in Disease Risk

The results showed that for some conditions, such as fatty liver disease, glucose intolerance, and knee replacement, the genetic link to disease disappeared when BMI was taken into account. For other conditions, like type 2 diabetes, heart failure, and stroke, the effects were largely reduced but not entirely explained by BMI. The results showed that for some conditions, such as fatty liver disease, glucose intolerance, and knee replacement, the genetic link to disease disappeared when BMI…
PR Newswire
12/11/2024

Access Accelerated and the World Bank Collaborate via New Technical Partnership…

The Financing Accelerator Network for NCDs aims to address this challenge by supporting governments and local stakeholders in strengthening their NCD response and building more resilient health financing systems, with a focus on advancing universal health coverage and building strong primary healthcare systems – key goals within the 2030 Sustainable Development Goals. The Financing Accelerator Network for NCDs aims to address this challenge by supporting governments and local stakeholders in...
PR Newswire
12/11/2024

EDAN Unveils Latest Innovations for Global Healthcare at MEDICA 2024

Marking 10 years in the blood gas field, EDAN officially reaching audiences with i500 this year, as one of the world's smallest benchtop analyzers with true zero maintenance, delivering over 30 parameters per test. The new Blood Sampler offers safer sampling with size options, ensuring accuracy by reducing ion interference via calcium-balanced heparin-lithium coating. Expanding in IVD, EDAN introduces the H90 Series hematology analyzer, utilizing 3D fluorescence technology for precise RET, DIFF…
PR Newswire
12/11/2024

Tsingke Successfully Showcases Innovations at BIO-Europe 2024

A Hub for Partnerships and Collaboration A Hub for Partnerships and Collaboration Tsingke's booth attracted significant attention, with many attendees eager to explore potential collaborations. Hundreds of Industry professionals from various sectors, including pharmaceutical research, biotechnology, and academia, had deeply engaged with Tsingke's professional team and discovered how its solutions can help researchers accelerate their work and address complex challenges in a variety of...
PR Newswire
12/11/2024

Barts Health Implements Cynerio's Healthcare Cybersecurity Platform

To best serve their community, Barts Health has opted to implement Cynerio's full suite, including Network Detection and Response for Healthcare (NDR-H) technology designed to monitor network traffic and detect and respond to threats. Cynerio's NDR-H sits within the hospital's network and monitors traffic without interfering with traffic flow, identifying unusual traffic, performing analysis, and alerting team members to potential attacks that could impact their ability to provide care. To…
PR Newswire
12/11/2024

MintNeuro Secures £1M Investment to Advance Transformative Semiconductor…

Neurological disorders impact over a billion people globally and pose a significant social and economic burden. Current treatments, especially pharmaceuticals, are often ineffective or fail to provide long-term solutions. With drug development becoming increasingly costly and less productive, many patients are left without effective care options. Neural implants offer a promising alternative, yet traditional technologies remain bulky, power-intensive, and reliant on invasive surgeries that limit…
PR Newswire
12/11/2024

Agenda for Essity's Capital Markets Day Accelerating Profitable Growth

Register for Essity's Capital Markets Day here, November 15, 2024, at the latest. The day will not be livestreamed. Material from parts of the day will be available on Essity's website after the event. Register for Essity's Capital Markets Day here,November 15, 2024, at the latest. The day will not be livestreamed. Material from parts of the day will be available on Essity's website after the event. Agenda - Accelerating profitable growth–Magnus Groth, President and...
PR Newswire
12/11/2024

SciBase decides on a directed issue of approximately SEK 22.5 million and a…

"Our existing owners together with the new participating in the directed issue now secure our financial position. We think it is a statement of strength to be able to bring in new long-term owners in this market climate without a discount to market. We are in an expansive phase with a strong focus on the US market where we see strong growth and high interest among clinics, and where Nevisense has recently been recognized and supported by leading doctors for its ability to significantly…
PR Newswire
12/11/2024

SciBase: Interim report January 1 - September 30, 2024

January - September in figures January - September in figures Important events during the quarter Important events after the end of the period This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET onNovember 12, 2024. This report has been comprehensively reviewed by the Company's auditors...
PR Newswire
12/11/2024

Turacoz Group bridging the gap between global and regional teams in medical…

Sharing the dais with Dr. Almudena Fraga, Director Global CX, Campaigns and Content in Marketing Operations, Lundbeck, Dr. Viraj Rajadhyaksha, Area Medical Director, AstraZeneca and Dr. Maged Saleh, Global BAVENCIO® Peer-to-Peer Marketing Lead, Merck, the panel discussed about the existing gaps between the global and local content creation teams, how these gaps can be better bridged by better collaboration, how the insights collected can be shared across teams to be integrated with the overall…
PR Newswire
12/11/2024
Altri  Comunicati